Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies
- PMID: 28413986
- DOI: 10.2174/1567205014666170417111859
Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies
Abstract
Objective: Alzheimer's disease (AD), the most important progressive neurodegenerative disorder, is characterized by cognitive and behavioral disabilities. Nowadays, tau, as a microtubuleassociated protein and a principle neuropathological hallmark of AD, provides us a neoteric perspective to explore further aetiopathogenesis and therapeutic strategy. The hyperphosphorylation and abnormal aggregation of tau, combined with its decreased clearance, form neurofibrillary tangles (NFTs) and exert neurotoxicity in AD.
Methods: Recent investigations aim to prevent the deposition of NFT and accelerate the clearance of NFT. Intriguingly, immunization strategies targeting tau effectively ameliorates the tau-associated pathology in AD. In addition, modified therapies targeting tau should be regarded as a potential way to treat AD. These progresses open new avenues for AD.
Conclusion: Here, we review the recent literature of potential mechanisms of the tau in AD and discuss the modified therapeutic strategies for AD.
Keywords: Alzheimer's disease; NFTs; Tau; aggregation; phosphorylation; therapy..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Similar articles
-
Pathological Changes of Tau Related to Alzheimer's Disease.ACS Chem Neurosci. 2019 Feb 20;10(2):931-944. doi: 10.1021/acschemneuro.8b00457. Epub 2018 Oct 23. ACS Chem Neurosci. 2019. PMID: 30346708 Review.
-
Tau aggregation is a therapeutic target for Alzheimer's disease.Curr Alzheimer Res. 2010 Dec;7(8):665-9. doi: 10.2174/156720510793611600. Curr Alzheimer Res. 2010. PMID: 20678070 Review.
-
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition.Mol Neurodegener. 2025 May 27;20(1):60. doi: 10.1186/s13024-025-00854-9. Mol Neurodegener. 2025. PMID: 40426267 Free PMC article.
-
Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer's disease.J Chem Neuroanat. 2001 Jul;22(1-2):65-77. doi: 10.1016/s0891-0618(01)00096-5. J Chem Neuroanat. 2001. PMID: 11470555
-
Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease.J Neurogenet. 2011 Dec;25(4):127-33. doi: 10.3109/01677063.2011.626471. J Neurogenet. 2011. PMID: 22091726 Review.
Cited by
-
Caspase-1 variant influencing CSF tau and FDG PET levels in non-demented elders from the ADNI cohort.BMC Neurol. 2022 Feb 16;22(1):59. doi: 10.1186/s12883-022-02582-9. BMC Neurol. 2022. PMID: 35172755 Free PMC article.
-
Neuropathological Mechanisms Associated with Pesticides in Alzheimer's Disease.Toxics. 2020 Mar 25;8(2):21. doi: 10.3390/toxics8020021. Toxics. 2020. PMID: 32218337 Free PMC article.
-
ReMAPping the microtubule landscape: How phosphorylation dictates the activities of microtubule-associated proteins.Dev Dyn. 2018 Jan;247(1):138-155. doi: 10.1002/dvdy.24599. Epub 2017 Oct 27. Dev Dyn. 2018. PMID: 28980356 Free PMC article. Review.
-
An Update of Salivary Biomarkers for the Diagnosis of Alzheimer's Disease.Int J Mol Sci. 2025 Feb 26;26(5):2059. doi: 10.3390/ijms26052059. Int J Mol Sci. 2025. PMID: 40076682 Free PMC article. Review.
-
Porphyromonas gingivalis outer membrane vesicles alter cortical neurons and Tau phosphorylation in the embryonic mouse brain.PLoS One. 2025 Mar 11;20(3):e0310482. doi: 10.1371/journal.pone.0310482. eCollection 2025. PLoS One. 2025. PMID: 40067832 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical